コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 dividuals with genetically distinct types of congenital muscular dystrophy.
2 type II cobblestone lissencephaly as seen in congenital muscular dystrophy.
3 utant could be a novel mechanism that causes congenital muscular dystrophy.
4 of the COL6A2 gene, in patients with Ullrich congenital muscular dystrophy.
5 ues, and mutations in its gene are causes of congenital muscular dystrophy.
6 ted muscular dystrophy, and alpha 7 integrin congenital muscular dystrophy.
7 ess very low levels of LM alpha2 and exhibit congenital muscular dystrophy.
8 iant, the dy2J/dy2J mouse, animal models for congenital muscular dystrophy.
9 mb-girdle muscular dystrophy and one form of congenital muscular dystrophy.
10 process should be considered consistent with congenital muscular dystrophy.
11 q22, is deficient in about half the cases of congenital muscular dystrophy.
12 r expression are the causes of some types of congenital muscular dystrophy.
13 assessment of laminin-2 (merosin) status in congenital muscular dystrophy.
14 skin biopsy specimens from two patients with congenital muscular dystrophy.
15 variants in human CHKB are associated with a congenital muscular dystrophy.
16 ker-Warburg syndrome (WWS), a severe form of congenital muscular dystrophy.
17 severity ranging from mild LGMD2I to severe congenital muscular dystrophy.
18 nge from Walker-Warburg syndrome to Fukuyama congenital muscular dystrophy.
19 yelination and is disrupted in some types of congenital muscular dystrophy.
20 ted episodes of rhabdomyolysis, and one as a congenital muscular dystrophy.
21 th broad severity, including limb-girdle and congenital muscular dystrophy.
22 mild Bethlem myopathy to the severe Ullrich congenital muscular dystrophy.
23 t dystroglycan receptor function and lead to congenital muscular dystrophy.
24 ies associated with laminin-alpha2-deficient congenital muscular dystrophy.
25 ion is associated with various phenotypes of congenital muscular dystrophy.
26 alpha-DG and are causal for various forms of congenital muscular dystrophy.
27 annosylation are causal for various forms of congenital muscular dystrophy.
28 muscle-eye-brain disease, and Fukuyama-type congenital muscular dystrophy.
29 nderstanding of the mechanisms that underlie congenital muscular dystrophy.
30 binding with laminin underlies a subclass of congenital muscular dystrophy.
31 y that similar synaptic defects occur in the congenital muscular dystrophies.
32 c strategy for glycosyltransferase-deficient congenital muscular dystrophies.
33 sylation of alpha-dystroglycan gives rise to congenital muscular dystrophies.
34 arating the TMTC3 COB phenotype from typical congenital muscular dystrophies.
35 congenital disorders of glycosylation to the congenital muscular dystrophies.
36 inhibit muscle pathology in mouse models of congenital muscular dystrophy 1A and Duchenne muscular d
37 mouse models of Duchenne muscular dystrophy, congenital muscular dystrophy 1A, and limb girdle muscul
38 irdle muscular dystrophy 2I (LGMD2I), severe congenital muscular dystrophy 1C (MDC1C), to Walker-Warb
40 he fukutin-related protein (FKRP) gene cause congenital muscular dystrophy 1C, typically lacking brai
42 Fukuyama congenital muscular dystrophy, and congenital muscular dystrophy 1D, are caused by mutation
44 he mutated gene product that causes Fukuyama congenital muscular dystrophy), a group of enzymes with
45 the dyW/dyW mouse model of laminin-deficient congenital muscular dystrophy, a much more severe and le
47 ent underlies cortical lamination defects in congenital muscular dystrophies and a cellular mechanism
49 e cerebellar atrophy), myopathies (including congenital muscular dystrophies and limb-girdle dystroph
50 cular dystrophy and forms of limb-girdle and congenital muscular dystrophies, and 21 patients had fal
51 onial congenital muscular dystrophy, Ullrich congenital muscular dystrophy, and alpha-dystroglycanopa
52 syndrome, muscle-eye-brain disease, Fukuyama congenital muscular dystrophy, and congenital muscular d
53 nsferase 2 (POMT2) are known to cause severe congenital muscular dystrophy, and recently, mutations i
56 ts suggest that the pathogenic mechanisms in congenital muscular dystrophy are different from those i
57 s with muscle-eye-brain disease and Fukuyama congenital muscular dystrophy, as well as mice with myod
58 ers known as dystroglycanopathies, which are congenital muscular dystrophies associated with brain an
59 ention as a pathomechanism underlying severe congenital muscular dystrophies associated with neuronal
60 n VI-related myopathies' and include Ullrich congenital muscular dystrophy, Bethlem myopathy and inte
61 rein the affected individuals presented with congenital muscular dystrophy, brain abnormalities and g
62 cts in type 2 (cobblestone) lissencephaly or congenital muscular dystrophies but appear later in cort
63 ation was initiated in patients with Ullrich congenital muscular dystrophy by 11.3 years (+/-4.0) and
66 ebral cortical malformations in syndromes of congenital muscular dystrophies caused by defects in O-m
67 the cell and molecular changes that occur in congenital muscular dystrophies caused by Lama2 mutation
68 in some of the pathogenic events observed in congenital muscular dystrophy caused by merosin deficien
69 muscular dystrophy (MDC1A) is a devastating congenital muscular dystrophy caused by mutations in the
72 s (POMTs) result in severe brain defects and congenital muscular dystrophies characterized by abnorma
73 tion result in dystroglycanopathy, a type of congenital muscular dystrophy characterized by a wide ra
75 NA gene variants L35P and R249Q, which cause congenital muscular dystrophy (CMD) and dilated cardiomy
81 association with dystroglycanopathy types of congenital muscular dystrophies (CMDs) and ocular abnorm
82 mbrane underlie neural ectopia seen in those congenital muscular dystrophies (CMDs) caused by mutatio
84 the most common causes of a severe group of congenital muscular dystrophies (CMDs) known as dystrogl
85 oup of neurodevelopmental disorders known as congenital muscular dystrophies (CMDs) with associated C
86 sease (MEB), and Walker-Warburg syndrome are congenital muscular dystrophies (CMDs) with associated d
87 mb girdle muscular dystrophy 2I (LGMD2I) and congenital muscular dystrophies (CMDs) with brain malfor
88 ts in protein O-mannosylation lead to severe congenital muscular dystrophies collectively known as a-
89 ses, POMT1 and POMT2, underlie a subgroup of congenital muscular dystrophies designated alpha-dystrog
91 ic muscles of mice representing Duchenne and congenital muscular dystrophies (DMD and CMD, respective
93 Muscle eye brain disease (MEB) and Fukuyama congenital muscular dystrophy (FCMD) are congenital musc
94 muscle-eye-brain disease (MEB) and Fukuyama congenital muscular dystrophy (FCMD), as well as the myo
95 scular dystrophy (CMD) such as Fukuyama type congenital muscular dystrophy (FCMD), Muscle-Eye-Brain d
97 utin, the defective protein in Fukuyama-type congenital muscular dystrophy (FCMD), that is thought to
99 anges (G76R and V428D) that result in severe congenital muscular dystrophies in humans, in yeast Pmt4
102 n in combination with cobblestone cortex and congenital muscular dystrophy in individuals with dystro
103 r dystrophy type 1A (MDC1A), the most common congenital muscular dystrophy in Western countries, is c
104 ypic effects of altered glycosylation in the congenital muscular dystrophies, including Walker-Warbur
109 nts with Bethlem myopathy, merosin-deficient congenital muscular dystrophy, LGMD2A, Duchenne muscular
114 the functions of Tmem2 and the etiologies of congenital muscular dystrophies, particularly dystroglyc
115 onstrate that this mechanism is disrupted in congenital muscular dystrophy patient myotubes carrying
117 ns in the LARGE gene have been identified in congenital muscular dystrophy patients with brain abnorm
118 adult onset myotonic dystrophy patients, two congenital muscular dystrophy patients, four normal cont
120 3galnt2 in zebrafish recapitulated the human congenital muscular dystrophy phenotype with reduced mot
121 ation result in dystroglycanopathies: severe congenital muscular dystrophy phenotypes often accompani
124 ant overlap in pathogenesis between LGMD and congenital muscular dystrophies, prompting further resea
126 phenotypic overlap were due to mutations in congenital muscular dystrophy-related genes (4 families)
127 of LARGE into the cells of individuals with congenital muscular dystrophies restores alpha-DG recept
129 MDC1A, the second most prevalent form of congenital muscular dystrophy, results from laminin-alph
130 ne muscular dystrophy (DMD), alpha 2 laminin congenital muscular dystrophy, sarcoglycan-related muscu
131 lso, approximately half of the patients with congenital muscular dystrophy show deficiency of a compo
132 ion lead to dystroglycanopathies, a group of congenital muscular dystrophies showing extreme genetic
133 demonstrate that mutations in INPP5K cause a congenital muscular dystrophy syndrome with short statur
134 n are characteristic features of a subset of congenital muscular dystrophies that include Walker-Warb
135 burg syndrome (WWS) is clinically defined as congenital muscular dystrophy that is accompanied by a v
136 ne glycoprotein dystroglycan cause a form of congenital muscular dystrophy that is frequently associa
137 5 subunits are expressed in alpha2-deficient congenital muscular dystrophy, they may be ineffective s
138 prevalence of 0.89/100 000 for the group of congenital muscular dystrophies to conditions with only
140 r dystroglycanopathy phenotypes ranging from congenital muscular dystrophy to limb-girdle muscular dy
141 bnormalities ranging from the severe Ullrich congenital muscular dystrophy to the mild Bethlem myopat
142 g of Fktn, the gene responsible for Fukuyama congenital muscular dystrophy, to investigate a developm
149 of a disease-modifying gene associated with congenital muscular dystrophy type 1A (MDC1A) using the
152 cal efficacy of bortezomib administration in congenital muscular dystrophy type 1A clinical trials ma
155 n, bortezomib reduced proteasome activity in congenital muscular dystrophy type 1A myoblasts and myot
157 related protein (FKRP) gene in patients with congenital muscular dystrophy type 1C (MDC1C) and limb g
158 FKRP) cause a spectrum of diseases including congenital muscular dystrophy type 1C (MDC1C), limb gird
164 in any of the three collagen VI genes cause congenital muscular dystrophy types Bethlem and Ullrich
166 ions in collagen VI result in either Ullrich congenital muscular dystrophy (UCMD) or Bethlem myopathy
168 3, have recently been shown to cause Ullrich congenital muscular dystrophy (UCMD), a frequently sever
169 of clinical phenotypes, ranging from Ullrich congenital muscular dystrophy (UCMD), presenting with pr
172 nal mechanisms are known to underlie Ullrich congenital muscular dystrophy (UCMD): heterozygous domin
173 MDs; Duchenne muscular dystrophy, megaconial congenital muscular dystrophy, Ullrich congenital muscul
174 nditions ranging from the most severe of the congenital muscular dystrophies, Walker-Warburg syndrome
175 has been reported in some clinical cases of congenital muscular dystrophy, we have begun to examine
176 rming to the original description of Ullrich congenital muscular dystrophy were easily identified by
177 n, a protein responsible for the majority of congenital muscular dystrophies when dysfunctional, has
178 in a group of patients with merosin-positive congenital muscular dystrophy, where it is generally ass
180 COL6) is known for its role in a spectrum of congenital muscular dystrophies, which are often accompa
181 ama congenital muscular dystrophy (FCMD) are congenital muscular dystrophies with associated, similar
184 rders such as Lowe and Joubert syndromes and congenital muscular dystrophy with cataracts and intelle
185 rotein varies from a severe prenatal form of congenital muscular dystrophy with cobblestone lissencep
186 acetyllactosamine synthesis, were causal for congenital muscular dystrophy with hypoglycosylation of